← All trials
NCT06195540
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 19, 2024
- Primary completion
- Nov 19, 2026
- Completion date
- Nov 19, 2026
- First posted
- Jan 8, 2024
- Last posted
- Aug 29, 2024
- Enrollment
- 1424
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of AngersLead sponsor
- University of AngersOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.